Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label EB-1020 (centanafadine) in pediatric ADHD (Japan-China phase III)
CTR20254976Phase 3Active
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of centanafadine in attention deficit hyperactivity disorder (ADHD), sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Mar 2026; status: active.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on CTR20254976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254976.